Published in Am J Physiol Endocrinol Metab on April 20, 2010
A novel humanized GLP-1 receptor model enables both affinity purification and Cre-LoxP deletion of the receptor. PLoS One (2014) 1.47
The structure and function of the glucagon-like peptide-1 receptor and its ligands. Br J Pharmacol (2012) 1.10
Recombinant expression, purification, and functional characterisation of connective tissue growth factor and nephroblastoma-overexpressed protein. PLoS One (2010) 0.79
Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes. Pharmacol Rev (2016) 0.78
N-linked glycosylation is required for transferrin-induced stabilization of transferrin receptor 2, but not for transferrin binding or trafficking to the cell surface. Biochemistry (2013) 0.78
The regions within the N-terminus critical for human glucagon like peptide-1 receptor (hGLP-1R) cell surface expression. Sci Rep (2014) 0.77
Optimized protocol for expression and purification of membrane-bound PglB, a bacterial oligosaccharyl transferase. Protein Expr Purif (2013) 0.77
The atypical N-glycosylation motif, Asn-Cys-Cys, in human GPR109A is required for normal cell surface expression and intracellular signaling. FASEB J (2015) 0.76
Improved functional expression of human cardiac kv1.5 channels and trafficking-defective mutants by low temperature treatment. PLoS One (2014) 0.75
The putative signal peptide of glucagon-like peptide-1 receptor is not required for receptor synthesis but promotes receptor expression. Biosci Rep (2014) 0.75
The human cytomegalovirus chemokine receptor homolog encoded by US27. Virus Genes (2017) 0.75
N-Glycosylation of Asparagine 130 in the Extracellular Domain of the Human Calcitonin Receptor Significantly Increases Peptide Hormone Affinity. Biochemistry (2017) 0.75
Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem (1980) 28.03
Glycobiology. Annu Rev Biochem (1988) 4.51
Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther (2006) 2.71
Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. J Biol Chem (2008) 2.51
Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor. J Biol Chem (2009) 1.94
Relationship between native and recombinant cholecystokinin receptors: role of differential glycosylation. Pancreas (1996) 1.46
Structure and function in rhodopsin. Requirements of a specific structure for the intradiscal domain. J Biol Chem (1994) 1.30
Multiple extracellular loop domains contribute critical determinants for agonist binding and activation of the secretin receptor. J Biol Chem (1996) 1.16
Identification of the sites of N-linked glycosylation on the human calcium receptor and assessment of their role in cell surface expression and signal transduction. J Biol Chem (1998) 1.15
Intrinsic photoaffinity labeling of native and recombinant rat pancreatic secretin receptors. Gastroenterology (1993) 1.13
Role of N-glycosylation in the expression and functional properties of human AT1 receptor. Biochemistry (1999) 1.11
Glycosylation of G-protein-coupled receptors for hormones central to normal reproductive functioning: its occurrence and role. Hum Reprod Update (1999) 1.09
Pattern of intra-family hetero-oligomerization involving the G-protein-coupled secretin receptor. J Mol Neurosci (2008) 1.05
Intracellularly located misfolded glycoprotein hormone receptors associate with different chaperone proteins than their cognate wild-type receptors. Mol Endocrinol (2004) 1.04
Molecular basis of glucagon-like peptide 1 docking to its intact receptor studied with carboxyl-terminal photolabile probes. J Biol Chem (2009) 1.04
Mutagenesis of N-glycosylation sites in the human vasoactive intestinal peptide 1 receptor. Evidence that asparagine 58 or 69 is crucial for correct delivery of the receptor to plasma membrane. Biochemistry (1996) 1.02
Role of glycosylation in expression and function of the human parathyroid hormone/parathyroid hormone-related protein receptor. Biochemistry (1996) 0.99
Insights into the structural basis of endogenous agonist activation of family B G protein-coupled receptors. Mol Endocrinol (2008) 0.98
Molecular basis of association of receptor activity-modifying protein 3 with the family B G protein-coupled secretin receptor. Biochemistry (2009) 0.97
Influence of the N-linked oligosaccharides on the biosynthesis, intracellular routing, and function of the human asialoglycoprotein receptor. J Biol Chem (1984) 0.96
Role of the signal peptide in the synthesis and processing of the glucagon-like peptide-1 receptor. Br J Pharmacol (2009) 0.94
Role of N-glycan-dependent quality control in the cell-surface expression of the AT1 receptor. Biochem Biophys Res Commun (2005) 0.91
N-glycosylation of CRF receptor type 1 is important for its ligand-specific interaction. Am J Physiol Endocrinol Metab (2001) 0.90
Role of asparagine-linked oligosaccharides in the function of the rat PTH/PTHrP receptor. Biochemistry (2000) 0.89
Glycosylation of the GLP-1 receptor is a prerequisite for regular receptor function. Peptides (1994) 0.89
N-linked glycosylation of the human bradykinin B2 receptor is required for optimal cell-surface expression and coupling. Biol Chem (2004) 0.87
Glycosylation is important for binding to human calcitonin receptors. Biochemistry (1999) 0.85
Glycosylation of human CRLR at Asn123 is required for ligand binding and signaling. Biochim Biophys Acta (2001) 0.85
Glycosylation of the calcitonin receptor-like receptor at Asn(60) or Asn(112) is important for cell surface expression. FEBS Lett (2000) 0.82
Role of N-linked glycosylation on the function and expression of the human secretin receptor. Endocrinology (1999) 0.81
Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev (2010) 3.27
Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology (2002) 2.76
International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev (2003) 2.25
Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res (2007) 1.73
Possible endogenous agonist mechanism for the activation of secretin family G protein-coupled receptors. Mol Pharmacol (2006) 1.72
Transmembrane segment IV contributes a functionally important interface for oligomerization of the Class II G protein-coupled secretin receptor. J Biol Chem (2007) 1.55
Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol (2010) 1.49
Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations. Proc Natl Acad Sci U S A (2013) 1.46
Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. Cancer Res (2006) 1.29
Spatial approximation between the amino terminus of a peptide agonist and the top of the sixth transmembrane segment of the secretin receptor. J Biol Chem (2003) 1.26
Constitutive formation of oligomeric complexes between family B G protein-coupled vasoactive intestinal polypeptide and secretin receptors. Mol Pharmacol (2005) 1.23
Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling. J Biol Chem (2011) 1.22
Molecular approximation between a residue in the amino-terminal region of calcitonin and the third extracellular loop of the class B G protein-coupled calcitonin receptor. J Biol Chem (2004) 1.21
Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation. J Biol Chem (2011) 1.19
Heterodimerization of type A and B cholecystokinin receptors enhance signaling and promote cell growth. J Biol Chem (2003) 1.17
Molecular approximations between residues 21 and 23 of secretin and its receptor: development of a model for peptide docking with the amino terminus of the secretin receptor. Mol Pharmacol (2007) 1.16
Environment and mobility of a series of fluorescent reporters at the amino terminus of structurally related peptide agonists and antagonists bound to the cholecystokinin receptor. J Biol Chem (2002) 1.15
Mapping spatial approximations between the amino terminus of secretin and each of the extracellular loops of its receptor using cysteine trapping. FASEB J (2012) 1.13
Functional importance of a structurally distinct homodimeric complex of the family B G protein-coupled secretin receptor. Mol Pharmacol (2009) 1.12
Dimeric arrangement of the parathyroid hormone receptor and a structural mechanism for ligand-induced dissociation. J Biol Chem (2010) 1.10
A misspliced form of the cholecystokinin-B/gastrin receptor in pancreatic carcinoma: role of reduced sellular U2AF35 and a suboptimal 3'-splicing site leading to retention of the fourth intron. Cancer Res (2002) 1.10
Dimerization in the absence of higher-order oligomerization of the G protein-coupled secretin receptor. Biochim Biophys Acta (2008) 1.10
Spatial approximation between secretin residue five and the third extracellular loop of its receptor provides new insight into the molecular basis of natural agonist binding. Mol Pharmacol (2008) 1.06
Molecular basis of secretin docking to its intact receptor using multiple photolabile probes distributed throughout the pharmacophore. J Biol Chem (2011) 1.06
Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands. J Med Chem (2009) 1.06
Pattern of intra-family hetero-oligomerization involving the G-protein-coupled secretin receptor. J Mol Neurosci (2008) 1.05
Secretin receptor oligomers form intracellularly during maturation through receptor core domains. Biochemistry (2006) 1.05
Differential effects of modification of membrane cholesterol and sphingolipids on the conformation, function, and trafficking of the G protein-coupled cholecystokinin receptor. J Biol Chem (2004) 1.04
Importance of the amino terminus in secretin family G protein-coupled receptors. Intrinsic photoaffinity labeling establishes initial docking constraints for the calcitonin receptor. J Biol Chem (2003) 1.04
Molecular basis of glucagon-like peptide 1 docking to its intact receptor studied with carboxyl-terminal photolabile probes. J Biol Chem (2009) 1.04
Refinement of the conformation of a critical region of charge-charge interaction between cholecystokinin and its receptor. Mol Pharmacol (2002) 1.04
Silencing of secretin receptor function by dimerization with a misspliced variant secretin receptor in ductal pancreatic adenocarcinoma. Cancer Res (2002) 1.03
Transmembrane segment peptides can disrupt cholecystokinin receptor oligomerization without affecting receptor function. Biochemistry (2006) 1.03
Spatial approximations between residues 6 and 12 in the amino-terminal region of glucagon-like peptide 1 and its receptor: a region critical for biological activity. J Biol Chem (2010) 1.02
Structure and function of Norrin in assembly and activation of a Frizzled 4-Lrp5/6 complex. Genes Dev (2013) 1.01
Secretin occupies a single protomer of the homodimeric secretin receptor complex: insights from photoaffinity labeling studies using dual sites of covalent attachment. J Biol Chem (2010) 1.01
Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation. Mol Pharmacol (2011) 1.00
Molecular characterization and distribution of motilin family receptors in the human gastrointestinal tract. J Gastroenterol (2006) 0.99
Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor. Br J Pharmacol (2009) 0.99
Importance of each residue within secretin for receptor binding and biological activity. Biochemistry (2011) 0.98
Insights into the structural basis of endogenous agonist activation of family B G protein-coupled receptors. Mol Endocrinol (2008) 0.98
Quiescin sulfhydryl oxidase 1 promotes invasion of pancreatic tumor cells mediated by matrix metalloproteinases. Mol Cancer Res (2011) 0.98
Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor. J Med Chem (2006) 0.97
Molecular basis of association of receptor activity-modifying protein 3 with the family B G protein-coupled secretin receptor. Biochemistry (2009) 0.97
Spatial approximation between a photolabile residue in position 13 of secretin and the amino terminus of the secretin receptor. Mol Pharmacol (2003) 0.97
Paired cysteine mutagenesis to establish the pattern of disulfide bonds in the functional intact secretin receptor. J Biol Chem (2005) 0.96
Molecular pharmacology of the secretin receptor. Receptors Channels (2002) 0.96
Fluorescence resonance energy transfer analysis of secretin docking to its receptor: mapping distances between residues distributed throughout the ligand pharmacophore and distinct receptor residues. J Biol Chem (2007) 0.96
Use of probes with fluorescence indicator distributed throughout the pharmacophore to examine the peptide agonist-binding environment of the family B G protein-coupled secretin receptor. J Biol Chem (2005) 0.96
CCK(2) receptor splice variant with intron 4 retention in human gastrointestinal and lung tumours. J Cell Mol Med (2009) 0.95
Benzodiazepine ligands can act as allosteric modulators of the Type 1 cholecystokinin receptor. Bioorg Med Chem Lett (2008) 0.95
Insights into interactions between the alpha-helical region of the salmon calcitonin antagonists and the human calcitonin receptor using photoaffinity labeling. J Biol Chem (2005) 0.94
Fluorescent indicators distributed throughout the pharmacophore of cholecystokinin provide insights into distinct modes of binding and activation of type A and B cholecystokinin receptors. J Biol Chem (2006) 0.94
Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors. J Med Chem (2009) 0.93
Differential sensitivity of types 1 and 2 cholecystokinin receptors to membrane cholesterol. J Lipid Res (2011) 0.93
Molecular basis for binding and subtype selectivity of 1,4-benzodiazepine antagonist ligands of the cholecystokinin receptor. J Biol Chem (2012) 0.92
Distinct molecular mechanisms for agonist peptide binding to types A and B cholecystokinin receptors demonstrated using fluorescence spectroscopy. J Biol Chem (2004) 0.92
Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) differentially regulates orthosteric but not allosteric agonist binding and function. J Biol Chem (2011) 0.90
Analysis of the cellular and molecular mechanisms of trophic action of a misspliced form of the type B cholecystokinin receptor present in colon and pancreatic cancer. Cancer Lett (2005) 0.90
Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist, and antagonist. Mol Pharmacol (2004) 0.90
Minireview: Signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discovery. Mol Endocrinol (2013) 0.89
Disulfide bond structure and accessibility of cysteines in the ectodomain of the cholecystokinin receptor: specific mono-reactive receptor constructs examine charge-sensitivity of loop regions. Receptors Channels (2003) 0.89
Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery. Proc Natl Acad Sci U S A (2012) 0.89
Juxtamembranous region of the amino terminus of the family B G protein-coupled calcitonin receptor plays a critical role in small-molecule agonist action. J Biol Chem (2009) 0.88
Fluorescence resonance energy transfer analysis of the antagonist- and partial agonist-occupied states of the cholecystokinin receptor. J Biol Chem (2005) 0.88
Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling. Biochemistry (2005) 0.88
Sensitivity of cholecystokinin receptors to membrane cholesterol content. Front Endocrinol (Lausanne) (2012) 0.87
Molecular basis for benzodiazepine agonist action at the type 1 cholecystokinin receptor. J Biol Chem (2013) 0.87
Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function. Biochem Soc Trans (2013) 0.87
Interaction among four residues distributed through the secretin pharmacophore and a focused region of the secretin receptor amino terminus. Mol Endocrinol (2002) 0.87
Functional and structural diversification of the Anguimorpha lizard venom system. Mol Cell Proteomics (2010) 0.87
Measurement of intermolecular distances for the natural agonist Peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy transfer. Mol Pharmacol (2004) 0.87
Importance of lipid-exposed residues in transmembrane segment four for family B calcitonin receptor homo-dimerization. Regul Pept (2010) 0.87
Secretin receptors in the human liver: expression in biliary tract and cholangiocarcinoma, but not in hepatocytes or hepatocellular carcinoma. J Hepatol (2006) 0.86
Risk factors for pancreatic adenocarcinoma and prospects for screening. Gastroenterol Hepatol (N Y) (2010) 0.86
Modulation of β-catenin signaling by glucagon receptor activation. PLoS One (2012) 0.86
Lactam constraints provide insights into the receptor-bound conformation of secretin and stabilize a receptor antagonist. Biochemistry (2011) 0.85
Dominant negative action of an abnormal secretin receptor arising from mRNA missplicing in a gastrinoma. Gastroenterology (2002) 0.85
Modulation of cell surface expression of nonactivated cholecystokinin receptors using bivalent ligand-induced internalization. J Med Chem (2010) 0.84
Krüppel-like factor 11 regulates the expression of metabolic genes via an evolutionarily conserved protein interaction domain functionally disrupted in maturity onset diabetes of the young. J Biol Chem (2013) 0.84
Elucidation of the molecular basis of cholecystokinin Peptide docking to its receptor using site-specific intrinsic photoaffinity labeling and molecular modeling. Biochemistry (2009) 0.84
Effects of cholecystokinin-58 on type 1 cholecystokinin receptor function and regulation. Am J Physiol Gastrointest Liver Physiol (2008) 0.84
Biochemical and cell biological mechanisms of cholecystokinin receptor regulation. Curr Top Med Chem (2007) 0.84
Extent and diversity of human alternative splicing established by complementary database annotation and microarray analysis. OMICS (2008) 0.84
Alternative splicing of pre-mRNA in cancer: focus on G protein-coupled peptide hormone receptors. Am J Pathol (2009) 0.83